Side-by-side · Research reference

GLP-1 (7-37)vsMatrixyl

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED16/43 cited

BAnimal-MechanisticHUMAN-REVIEWED9/39 cited

GLP-1 (7-37)

Incretin Hormone · Native Peptide

~2 minHalf-lifeAlavi 2021 Ding 2017

3297.7 DaMolecular weightAlavi 2021

1922Discovery year

Research use only · IV/SC in experimental settings

Matrixyl

Cosmeceutical Pentapeptide · Topical Anti-Aging

TopicalRoute

5-AALength (KTTKS)Gomes 2022

Collagen I/IIIPrimary targetPaccola 2025

Topical · Dermal · Twice Daily

01Mechanism of Action

Parameter

GLP-1 (7-37)

Matrixyl

Primary target

GLP-1 receptor (class B GPCR)Koole 2015

Dermal fibroblastsPaccola 2025

Pathway

GLP-1R activation → cAMP production → PKA signaling → insulin secretion (pancreatic β-cells)Lu 2025 Koole 2015

Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling

Downstream effect

Glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, reduced food intakeLu 2025 Ding 2017

Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025

Feedback intact?

Yes — physiological secretion and degradation preserved

—

Origin

Endogenous peptide cleaved from proglucagon in intestinal L cells; secreted postprandially

Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022

Antibody development

—

02Dosage Protocols

Parameter

GLP-1 (7-37)

Matrixyl

Clinical use

None — native GLP-1 not used therapeutically

Engineered analogues (semaglutide, liraglutide) used clinically.Friedman 2024

—

Research dosing

Variable — 0.1–10 nmol/kg in animal models

Used as reference standard for analogue comparison.

—

Half-life

~2 minutes (plasma)Alavi 2021 Ding 2017

Requires continuous infusion for sustained effect.

—

Modified analogues

t½ extended to 13 h (liraglutide), 165 h (semaglutide)

Via DPP-4 resistance + fatty acid acylation.

—

Formulation concentration

—

0.5–5% in topical vehicle

Common cosmeceutical range; higher concentrations in clinical formulations.

Application frequency

—

Twice daily (AM/PM)

Standard cosmeceutical protocol.

Duration

—

8–12 weeks minimum for visible effect

Collagen synthesis requires sustained application.

In vitro evidence

—

Fibroblast viability + ECM gene upregulationPaccola 2025

Vehicle

—

Serum, cream, or emulsion base

Lipophilic carriers enhance penetration.

03Metabolic / Fat Loss Evidence

Parameter

GLP-1 (7-37)

Matrixyl

Mechanism

GLP-1R activation in hypothalamic satiety centers (arcuate nucleus) reduces food intakeLu 2025

Effect demonstrated with long-acting analogues (liraglutide).Lu 2025

—

Native GLP-1 efficacy

Minimal — rapid degradation prevents sustained appetite suppression

—

Gastric emptying

Delayed in animal models, contributing to satiety

—

Body weight impact

Not observed with native GLP-1 — requires analogue formulations

—

04Side Effects & Safety

Parameter

GLP-1 (7-37)

Matrixyl

Native GLP-1

Well-tolerated in research settings; no prolonged exposure data

—

Hypoglycemia risk

Low — insulin secretion is glucose-dependent

—

Analogue side effects

Nausea, vomiting, diarrhea (GLP-1R agonists)

Not applicable to native GLP-1 due to non-therapeutic use.

—

GLP-1 resistance

High glucose-induced PKCβ overexpression may reduce GLP-1 responsiveness in endothelial cellsPujadas 2016

—

Irritation

—

Mild erythema, pruritus in sensitive skin (rare)

Allergic reaction

—

Contact dermatitis (uncommon)

Systemic absorption

—

Negligible — topical application only

Absolute Contraindications

GLP-1 (7-37)

—

Matrixyl

·Known hypersensitivity to palmitoyl peptides

Relative Contraindications

GLP-1 (7-37)

—

Matrixyl

·Active dermatitis or open wounds at application site

05Administration Protocol

Parameter

GLP-1 (7-37)

Matrixyl

1. Research use only

Native GLP-1(7-37) is not formulated for therapeutic use. Administered IV or SC in experimental protocols to study GLP-1R pharmacology and as reference standard for analogue development.

Wash face with gentle cleanser. Pat dry.

2. Storage

Lyophilised peptide stored at -20°C or below. Reconstituted solutions should be prepared fresh and used immediately due to rapid degradation.

Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.

3. Clinical alternatives

For therapeutic GLP-1R activation, use FDA-approved long-acting analogues: semaglutide (once weekly), liraglutide (once daily), dulaglutide (once weekly), or exenatide (twice daily or once weekly).

Twice daily — morning and evening. Apply before heavier creams or sunscreen.

4. Storage

—

Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.

06Stack Synergy

GLP-1 (7-37)

— no documented stacks

Matrixyl

+ GHK-Cu

Multi-pathway

View GHK-Cu →

Matrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.

Matrixyl: 0.5–5% topical serum · AM/PM
GHK-Cu: 1–2% topical serum · same application
Frequency: Twice daily
Primary benefit: Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity